

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. 1.56, 1.97, and 1.98)				ATTORNEY DOCKET		APPLICATION NO.	
				23117-0002 DIV 1		09/915, 412 Not Assigned	
				APPLICANT(S) Jacob Bar-Tana			
SHEET 1 OF 2				FILING DATE		GROUP	
				July 25, 2001		1623 Not Assigned	

1050 U.S. PTO
 09/915412
 07/25/01

U.S. PATENT DOCUMENTS						
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	U.S. CLASS/ SUBCLASS	FILING DATE (If appropriate)
W	*AA	4,634,795	01/87	Bar-Tana	562/590	
W	*AB	4,689,344	08/87	Bar-Tana	514/527	
W	*AC	4,711,896	12/87	Bar-Tana et al.	514/570	
W	*AD	5,641,810	06/97	Pill et al.	514/558	

FOREIGN PATENT DOCUMENTS					
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
W	*BA	119971	01/97	ISRAEL	
W	*BB	121165	06/97	ISRAEL	
W	*BC	WO 98/30530	07/98	PCT	

OTHER DOCUMENTS		
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
W	*CA	Bar-Tana et al., "Inhibition of lipid synthesis by β, β' tetramethyl-substituted C ₁₄ -C ₂₂ α, ω dicarboxylic acids in the rat <i>in vivo</i> ", <i>J. Biol. Chem.</i> , 260:8404-8410 (1985).
W	*CB	Bar-Tana et al., "Synthesis, hypolipidemic and antidiabetogenic activities of β, β' -tetra-substituted, long chain dioic acids", <i>J. Med. Chem.</i> , 32:2072-2084 (1989).
W	*CC	Bar-Tana, J., "Long chain dicarboxylic acids: Hypolipidemic, antiobesity and antidiabetic activity", In <i>New Antidiabetic Drugs</i> , (eds. BAILEY CJ, FLATT PR), Smity-Tordon and Comp. (1990).
W	*CD	Bar-Tana et al., "The hypolipidemic effect of β, β' -methyl-substituted hexadecanedioic acid in normal and nephrotic rats", <i>J. Lipid Res.</i> , 29:4431-4441 (1998).
W	*CE	DeFronzo et al., "Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease", <i>Diabetes Care</i> , 3:173-194 (1991).
W	*CF	Frenkel et al., "The hypocholesterolemic effect of β, β' -methyl-substituted hexadecanedioic acid is mediated by a decrease in apolipoprotein C-III", <i>J. Biol. Chem.</i> , 263:8491-8497 (1988).
W	*CG	Frenkel et al., "The effect of β, β' -methyl-substituted hexadecanedioic acid on plasma VLDL metabolism in rats: role of apolipoprotein C-III", <i>Biochem. J.</i> , 298:409-414 (1994).
W	*CH	Hermesh et al., "Mitochondria uncoupling by a long chain fatty acyl analogue", <i>J. Biol. Chem.</i> , In Press (1997).
W	*CI	Hertz et al., "Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III", <i>J. Biol. Chem.</i> , 270:13470-13475 (1995).
W	*CJ	Kahn-Rose et al., "Inhibition of lipid synthesis by β, β' tetramethyl-substituted C ₁₄ -C ₂₂ α, ω dicarboxylic acids in cultured rat hepatocytes", <i>J. Biol. Chem.</i> , 260:8411-8415 (1985).
W	*CK	Kalderon et al., "Tissue selective modulation of redox and phosphate potentials by β, β' -methyl- substituted hexadecanedioic acid", <i>Endocrinology</i> , 131:162-1635 (1992).
W	*CL	Limatta et al., "Dietary Polyunsaturated Fatty Acids Interfere with the Insulin/Glucose Activation of I-Type Pyruvate Kinase Gene Transcription", <i>Molecular Endocrinology</i> , 8: 1147-1153 (1994).

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. 1.56, 1.97, and 1.98)		ATTORNEY DOCKET		APPLICATION NO.	
		23117-0002 DIV 1		09/915,412	
		APPLICANT(S)			
		Jacob Bar-Tana			
SHEET 2 OF 2		FILING DATE		GROUP	
		July 25, 2001		1623	
		Not Assigned			

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
JW	*CM	Mayorek et al., "Hypocholesterolemic effect of β,β' -methyl-substituted hexadecanedioic acid in the male hamster", <i>Biochem. J.</i> , 289:911-917 (1993).
JW	*CN	Mayorek et al., "Sensitization to insulin induced by β,β' -methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats <i>in vivo</i> ", <i>Diabetes</i> , (1997).
JW	*CO	Russel et al., "The hypolipidemic effect of β,β' tetramethylhexadecanedioic acid (MEDICA 16) in hyperlipidemic JCR:LA-corpulent rats", <i>Arteriosclerosis and Thrombosis</i> , 11:602-609 (1991).
JW	*CP	Russell et al., "Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by β,β' -tetramethyl hexadecanedioic acid", <i>Arterioscler. Thromb. Vasc. Biol.</i> , 15:918-923 (1995).
JW	*CQ	Tzur et al., "The hypolipidemic antiobesity and hypoglycemic-hypoinsulinemic effects of β,β' -methyl-substituted hexadecanedioic acid in sand rats", <i>Diabetes</i> , 37:1618-1624 (1988).
JW	*CR	Tzur et al., "Adipose reduction by β,β' -tetramethyl-substituted hexadecanedioic acid (MEDICA 16)", <i>Int. J. Obesity</i> , 13:313-326 (1989).

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

E. White